Orphazyme investor following muscle wasting disappointment: "Now everything has to run smoothly in 2021"
The rest of 2021 has to run perfectly for Orphazyme, according to portfolio manager, following the pharmaceutical firm's recent and disappointing study with main candidate arimoclomol for the muscle wasting disease IBM.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
Following disappointing results for Orphazyme's main candidate arimoclomol against muscle wasting disease inclusion body myositis (IBM), which decreased the share price over 30 percent within a single trading day, the firm has two chances left which must be successful in order to set the company right again.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme share recovers somewhat after dive
For subscribers
